Health ❯ Healthcare ❯ Immunotherapy

Cancer Treatment

Patient-Specific Approaches Intratumoral Interactions Bifunctional Superkines PD-1 Inhibitors Research Innovations Non-Hodgkin Lymphoma Immune System Interaction Patient Experience Clinical Trials ANKTIVA® Antibody Development Targeted Therapies Bladder Cancer Vaccine Development Macrophages Targeted Therapy Tissue-Resident Memory T Cells Rare Diseases Bowel Cancer Vaccines Anktiva

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

The decision extends Anktiva’s reach across Europe to reinforce ImmunityBio’s commercial transition.

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Study Pinpoints GPR25 as Switch for Tissue-Resident Memory T Cell Formation

Antibody Blocking SLAMF6 Restores T-Cell Attack on AML in Preclinical Study

AI Drives Next-Generation Melanoma Immunotherapies Toward In Vivo Testing